The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Indole: A privileged scaffold for the design of anti-cancer agents
Open accessAbstract
In general, heterocyclic compounds are a significant source of pharmacologically active compounds. Among them, the indole scaffold widely distributes in natural products and bioactive molecules including anti-cancer agents. In view of its unique physic-chemical and biological properties, it has been used as a privileged scaffold in the anti-cancer agents design. So far, many natural and synthetic indole derivatives have been discovered as promising anti-cancer agents used in clinic or clinical evaluations, suggesting its prominent place in anti-cancer drugs development. This review aimed to provide a clear knowledge on the recent development of indoles as anti-cancer agents, such as myeloid cell leukemia-1 (Mcl-1) inhibitors, proviral insertion site in moloney murine leukemia virus (Pim) inhibitors, histone deacetylase (HDAC) inhibitors, silent mating type information regulation 2 homolog (SIRT) inhibitors and tubulin inhibitors, and made an insight into the corresponding structure-activity relationships (SARs). We hope the review could give a guide to develop new anti-cancer agents with greater potency against drug-sensitive and drug-resistant cancers in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase
Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y., et al. (2004) · Science · doi:10.1126/science.1094637 · Cited by 3,239
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase
Yeung, F., Hoberg, J. E., Ramsey, C. S., Keller, M. D., Jones, D. R., Frye, R. A., & Mayo, M. W. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600244 · Cited by 2,750
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Konopleva, M., Contractor, R., Tsao, T., Samudio, I., Ruvolo, P. P., Kitada, S., Deng, X., Zhai, D., Shi, Y.-X., Sneed, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.006 · Cited by 1,023
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Deacetylation of p53 modulates its effect on cell growth and apoptosis
Luo, J., Su, F., Chen, D., Shiloh, A., & Gu, W. (2000) · Nature · doi:10.1038/35042612 · Cited by 818
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
Wertz, I. E., Kusam, S., Lam, C., Okamoto, T., Sandoval, W., Anderson, D. J., Helgason, E., Ernst, J. A., Eby, M., Liu, J., et al. (2011) · Nature · doi:10.1038/nature09779 · Cited by 794
(2002) · PubMed · Cited by 732
Epigenetics and aging: the targets and the marks
Fraga, M. F., & Esteller, M. (2007) · Trends in Genetics · doi:10.1016/j.tig.2007.05.008 · Cited by 690
Theo Cuypers, H., Selten, G., Quint, W., Zijlstra, M., Maandag, E. R., Boelens, W., van Wezenbeek, P., Melief, C., & Berns, A. (1984) · Cell · doi:10.1016/0092-8674(84)90309-x · Cited by 639
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
Chadha, N., & Silakari, O. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.003 · Cited by 636
From Nature to Drug Discovery: The Indole Scaffold as a ‘Privileged Structure’
de Sa Alves, F., Barreiro, E., & Manssour Fraga, C. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709788452649 · Cited by 604
Discovery of Indoles as Potent and Selective Inhibitors of the Deacetylase SIRT1
Napper, A. D., Hixon, J., McDonagh, T., Keavey, K., Pons, J.-F., Barker, J., Yau, W. T., Amouzegh, P., Flegg, A., Hamelin, E., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050522v · Cited by 523
For better or for worse: the role of Pim oncogenes in tumorigenesis
Nawijn, M. C., Alendar, A., & Berns, A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2986 · Cited by 481
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
Atadja, P. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.019 · Cited by 419
Grant, S., Easley, C., & Kirkpatrick, P. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2227 · Cited by 412
The Critical Role of the Class III Histone Deacetylase SIRT1 in Cancer
Liu, T., Liu, P. Y., & Marshall, G. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3365 · Cited by 384
Brault, L., Gasser, C., Bracher, F., Huber, K., Knapp, S., & Schwaller, J. (2010) · Haematologica · doi:10.3324/haematol.2009.017079 · Cited by 368
Histone Deacetylase Inhibitors: From Bench to Clinic
Paris, M., Porcelloni, M., Binaschi, M., & Fattori, D. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7011408 · Cited by 367
Recent developments in tubulin polymerization inhibitors: An overview
Kaur, R., Kaur, G., Gill, R. K., Soni, R., & Bariwal, J. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.051 · Cited by 344
Indole in the target-based design of anticancer agents: A versatile scaffold with diverse mechanisms
Dadashpour, S., & Emami, S. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.065 · Cited by 343
Plumb, J. A., Finn, P. W., Williams, R. J., Bandara, M. J., Romero, M., Watkins, C. J., Thangue, N. B. L., & Brown, R. E. (2003) · PubMed · Cited by 312
Ning, Z.-Q., Li, Z.-B., Newman, M. J., Shan, S., Wang, X.-H., Pan, D.-S., Zhang, J., Dong, M., Du, X., & Lu, X.-P. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1766-x · Cited by 303
Friberg, A., Vigil, D., Zhao, B., Daniels, R. N., Burke, J. P., Garcia-Barrantes, P. M., Camper, D., Chauder, B. A., Lee, T., Olejniczak, E. T., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301448p · Cited by 300
Indole Alkaloids from Catharanthus roseus: Bioproduction and Their Effect on Human Health
Almagro, L., Fernández-Pérez, F., & Pedreño, M. (2015) · Molecules · doi:10.3390/molecules20022973 · Cited by 291
Pyrrole: An insight into recent pharmacological advances with structure activity relationship
Ahmad, S., Alam, O., Naim, M. J., Shaquiquzzaman, M., Alam, M. M., & Iqbal, M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.002 · Cited by 259
Panobinostat for the Treatment of Multiple Myeloma
Laubach, J. P., Moreau, P., San-Miguel, J. F., & Richardson, P. G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0530 · Cited by 255
Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Ali, I., Lone, M., Al-Othman, Z., Al-Warthan, A., & Sanagi, M. (2015) · Current Drug Targets · doi:10.2174/1389450116666150309115922 · Cited by 252
Cross‐Talk between Aging and Cancer: The Epigenetic Language
FRAGA, M. F., AGRELO, R., & ESTELLER, M. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1395.005 · Cited by 251
Epigenetics and cancer treatment
Kristensen, L. S., Nielsen, H. M., & Hansen, L. L. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.011 · Cited by 230
Li, L., Jiang, S., Li, X., Liu, Y., Su, J., & Chen, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.011 · Cited by 224
Research advances on anticancer activities of matrine and its derivatives: An updated overview
Rashid, H. U., Xu, Y., Muhammad, Y., Wang, L., & Jiang, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.037 · Cited by 205
Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains
Naaz, F., Haider, M. R., Shafi, S., & Yar, M. S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.025 · Cited by 203
Wei, G., Margolin, A. A., Haery, L., Brown, E., Cucolo, L., Julian, B., Shehata, S., Kung, A. L., Beroukhim, R., & Golub, T. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.028 · Cited by 183
Asati, V., Mahapatra, D. K., & Bharti, S. K. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.025 · Cited by 165
Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity
Bruncko, M., Wang, L., Sheppard, G. S., Phillips, D. C., Tahir, S. K., Xue, J., Erickson, S., Fidanze, S., Fry, E., Hasvold, L., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501258m · Cited by 164
Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines
Zhang, H., Guttikonda, S., Roberts, L., Uziel, T., Semizarov, D., Elmore, S. W., Leverson, J. D., & Lam, L. T. (2011) · Oncogene · doi:10.1038/onc.2010.559 · Cited by 164
Pelz, N. F., Bian, Z., Zhao, B., Shaw, S., Tarr, J. C., Belmar, J., Gregg, C., Camper, D. V., Goodwin, C. M., Arnold, A. L., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01660 · Cited by 161
Sherer, C., & Snape, T. J. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.007 · Cited by 160
Romidepsin for the treatment of cutaneous T-cell lymphoma
Campàs-Moya, C. (2009) · Drugs of today · doi:10.1358/dot.2009.45.11.1437052 · Cited by 157
Wei, S., Dong, K., Fang, L., Wang, X., Li, B., Shen, J., Zhang, Q., Wang, R., & Zhang, H. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0697-7 · Cited by 150
Development and Therapeutic Implications of Selective Histone Deacetylase 6 Inhibitors
Kalin, J. H., & Bergman, J. A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4001659 · Cited by 135
Development of Pyrazolone and Isoxazol-5-one Cambinol Analogues as Sirtuin Inhibitors
Mahajan, S. S., Scian, M., Sripathy, S. P., Posakony, J., Lao, U., Loe, T. K., Leko, V., Thalhofer, A., Schuler, A. D., Bedalov, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4018064 · Cited by 126
Jordan, M. A., Himes, R. H., & Wilson, L. (1985) · PubMed · Cited by 120
PIM kinase inhibitors: Structural and pharmacological perspectives
Asati, V., Mahapatra, D. K., & Bharti, S. K. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.050 · Cited by 108
Burke, J. P., Bian, Z., Shaw, S., Zhao, B., Goodwin, C. M., Belmar, J., Browning, C. F., Vigil, D., Friberg, A., Camper, D. V., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501984f · Cited by 105
Yap, J. L., Chen, L., Lanning, M. E., & Fletcher, S. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01888 · Cited by 104
HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors
Sangwan, R., Rajan, R., & Mandal, P. K. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.073 · Cited by 98
Crystal Structure of the PIM2 Kinase in Complex with an Organoruthenium Inhibitor
Bullock, A. N., Russo, S., Amos, A. L., Pagano, N., Bregman, H. S., Debreczeni, J. E., Lee, W. H., von Delft, F., Meggers, E., & Knapp, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007112 · Cited by 96
Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells
Cea, M., Soncini, D., Fruscione, F., Raffaghello, L., Garuti, A., Emionite, L., Morán, E., Magnone, M., Zoppoli, G. M., Reverberi, D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022739 · Cited by 95
Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents
Wan, Y., Dai, N., Tang, Z., & Fang, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.076 · Cited by 90
Self-citationHeinemann, A., Cullinane, C. M., Paoli‐Iseppi, R. D., Wilmott, J. S., Gunatilake, D., Madore, J., Strbenac, D., Yang, J. Y. H., Gowrishankar, K., Tiffen, J. C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4242 · Cited by 86
Li, X., Inks, E. S., Li, X., Hou, J., Chou, C. J., Zhang, J., Jiang, Y., Zhang, Y., & Xu, W. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401877m · Cited by 82
Antiproliferative Effect of Indole Phytoalexins
Chripková, M., Zigo, F., & Mojžíš, J. (2016) · Molecules · doi:10.3390/molecules21121626 · Cited by 82
Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups
Li, Y., Wang, F., Chen, X., Wang, J., Zhao, Y., Li, Y., & He, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190122144949 · Cited by 80
Self-citationWienecke-Baldacchino, A. K., & Bacher, G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1342 · Cited by 76
Lai, M.-J., Huang, H.-L., Pan, S., Liu, Y.-M., Peng, C.-Y., Lee, H., Yeh, T., Huang, P.-H., Teng, C., Chen, C., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300197a · Cited by 72
Ramya, P., Angapelly, S., Guntuku, L., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.043 · Cited by 71
Chen, X., Zhao, S., Li, H., Wang, X., Geng, A., Hao, C., Lu, T., Chen, Y., & Zhu, Y. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.032 · Cited by 69
Mahboobi, S., Sellmer, A., Höcher, H., Garhammer, C., Pongratz, H., Maier, T. M., Ciossek, T., & Beckers, T. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0703136 · Cited by 68
Moore, D. C. (2016) · PubMed Central · Cited by 67
Synthesis, molecular docking, and QSAR study of sulfonamide-based indoles as aromatase inhibitors
Pingaew, R., Mandi, P., Prachayasittikul, V., Prachayasittikul, S., Ruchirawat, S., & Prachayasittikul, V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.057 · Cited by 66
Discovery and biological characterization of potent myeloid cell leukemia‐1 inhibitors
Lee, T., Bian, Z., Zhao, B., Hogdal, L. J., Sensintaffar, J., Goodwin, C. M., Belmar, J., Shaw, S., Tarr, J. C., Veerasamy, N., et al. (2016) · FEBS Letters · doi:10.1002/1873-3468.12497 · Cited by 64
Purgatorio, R., de Candia, M., Catto, M., Carrieri, A., Pisani, L., Palma, A. D., Toma, M., Ivanova, O. A., Voskressensky, L. G., & Altomare, C. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.062 · Cited by 64
Niso, M., Abate, C., Contino, M., Ferorelli, S., Azzariti, A., Perrone, R., Colabufo, N. A., & Berardi, F. (2013) · ChemMedChem · doi:10.1002/cmdc.201300291 · Cited by 60
Sayed, M. T. E., Hamdy, N. A., Osman, D. A. A., & Ahmed, K. M. (2015) · Advances in Modern Oncology Research · doi:10.18282/amor.v1.i1.12 · Cited by 60
Panathur, N., Gokhale, N., Dalimba, U., Pulla, V. K., Yogeeswari, P., & Sriram, D. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.05.015 · Cited by 59
de Candia, M., Zaetta, G., Denora, N., Tricarico, D., Majellaro, M., Cellamare, S., & Altomare, C. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.037 · Cited by 59
Zhao, B., & He, T. (2014) · Oncology Reports · doi:10.3892/or.2014.3595 · Cited by 57
Colley, H. E., Muthana, M., Danson, S. J., Jackson, L. V., Brett, M. L., Harrison, J., Coole, S. F., Mason, D. P., Jennings, L. R., Wong, M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01312 · Cited by 56
Cheng, G., Wang, Z., Yang, J., Bao, Y. J., Xu, Q., Zhao, L., & Liu, D. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.12.011 · Cited by 54
Giannini, G., Marzi, M., Marzo, M. D., Battistuzzi, G., Pezzi, R., Brunetti, T., Cabri, W., Vesci, L., & Pisano, C. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.101 · Cited by 53
Belinostat for the treatment of peripheral T-cell lymphomas
Jimeno, A., & McDermott, J. D. (2014) · Drugs of today · doi:10.1358/dot.2014.50.5.2138703 · Cited by 51
Zhang, Y., Yang, P., Chou, C. J., Liu, C., Wang, X., & Xu, W. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300366t · Cited by 48
Chang, S., Christian, W., Wu, M.-H., Chen, T., Lin, Y.-W., Suen, C., Pidugu, H. B., Detroja, D., Shah, A. K., Hwang, M., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.046 · Cited by 44
Human SIRT1: A potential biomarker for tumorigenesis?
Lim, C. (2006) · Cell Biology International · doi:10.1016/j.cellbi.2006.11.003 · Cited by 43
Li, W., Sun, H., Xu, F., Wen, S., Liu, J., Xu, S., Yao, H., Ma, C., Zhu, Z., & Xu, J. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.12.015 · Cited by 43
Panathur, N., Dalimba, U., Pulla, V. K., Alvala, M., Yogeeswari, P., Sriram, D., & Kumar, V. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.08.018 · Cited by 36
Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors
Wu, B., Wang, H., Cee, V. J., Lanman, B. A., Nixey, T. E., Pettus, L. H., Reed, A. B., Wurz, R. P., Guerrero, N. T., Sastri, C. E., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.12.091 · Cited by 33
Cai, M., Hu, J., Tian, J., Yan, H., Zheng, C., & Hu, W. (2015) · Chinese Chemical Letters · doi:10.1016/j.cclet.2015.03.015 · Cited by 32
Ozcan, S., İnce, E., Akdemir, A., Ceylan, Ö. Ö., Süzen, S., & Gürer-Orhan, H. (2018) · Xenobiotica · doi:10.1080/00498254.2018.1482029 · Cited by 30
Layek, M., Kumar, Y., Islam, A., Karavarapu, R., Sengupta, A., Halder, D., Mukkanti, K., & Pal, M. (2011) · MedChemComm · doi:10.1039/c1md00029b · Cited by 29
Xu, G., Liu, T., Zhou, Y., Yang, X., & Fang, H. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.08.024 · Cited by 29
Jiao, J., Fang, H., Wang, X., Guan, P. F., Yuan, Y., & Xu, W. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.06.010 · Cited by 24
Liu, T., Wan, Y., Liu, R., Ma, L., Li, M., & Fang, H. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.02.014 · Cited by 24
Self-citationChen, C., Nie, Y., Xu, G., Yang, X., Fang, H., & Hou, X. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.05.003 · Cited by 20
Luan, S., Ge, Q. P., Chen, Y., Dai, M., Yang, J., Li, K., Liu, D., & Zhao, L. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.03.028 · Cited by 16
Discovery of a series of hydroximic acid derivatives as potent histone deacetylase inhibitors
Zhang, L., Wang, X., Li, X., Zhang, L., & Xu, W. (2013) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2013.827678 · Cited by 7
Cited by
Chalcone Derivatives: Role in Anticancer Therapy
Ouyang, Y., Li, J., Chen, X., Fu, X., Sun, S., & Wu, Q. (2021) · Biomolecules · doi:10.3390/biom11060894 · Cited by 399
Discovery of Potent and Selective Inhibitors against Protein-Derived Electrophilic Cofactors
Wang, X., Lin, Z., Bustin, K. A., McKnight, N. R., Parsons, W. H., & Matthews, M. L. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c12748 · Cited by 31
Metadata
- Authors
- Wan, Y., Li, Y., Yan, C., Yan, M., & Tang, Z.
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 183
- Pages
- 111691
- ISSN
- 0223-5234 (ISSN-L)
- OpenAlex
- W2972484391
- Cited by
- 516
- References
- 94
- FWCI
- 18.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.